Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination

Journal of Immunology

Volumn 176, Issue 10, 2006, Pages 6340-6346

  Nishikawa, Hiroyoshi ^a   Qian, Feng ^b   Tsuji, Takemasa ^a   Ritter, Gerd ^a   Old, Lloyd J ^a   Gnjatic, Sacha ^a   Odunsi, Kunle ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DP ANTIGEN; HLA DP4 ANTIGEN; NY ESO 1 ANTIGEN; PEPTIDE; SERYLLYSYLLYSYLMETHIONYLTRYPTOPHYLISOLEUCYLTHREONYLGLUTAMINYLCYSTEINYLPHENY LALANYLLYSYLPROLYLVALYLPHENYLALANYLLYSYLARGINYLGLUTAMINYLPROLINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; CANCER PATIENT; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; EFFECTOR CELL; HUMAN; HUMAN CELL; MEMORY T LYMPHOCYTE; OVARY CANCER; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; VACCINATION;

EID: 33646478274     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.10.6340     Document Type: Article

References (47)

1. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155: 1151-1164.
2. Maloy, K. J., and F. Powrie. 2001. Regulatory T cells in the control of immune pathology. Nat. Immunol. 2: 816-822.
3. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2: 389-400.
4. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22: 531-562.
5. Onizuka, S., I. Tawara, J. Shimizu, S. Sakaguchi, T. Fujita, and E. Nakayama. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res. 59: 3128-3133.
6. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163: 5211-5218.
7. + regulatory T cells in wild-type hosts. Proc. Natl. Acad. Sci. USA 102: 9253-9257.
8. + T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc. Natl. Acad. Sci. USA 100: 10902-10906.
9. + T-cell-dependent immune defense of B16 melanoma. Cancer Res. 61: 8643-8646.
10. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194: 823-832.
11. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949.
12. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98: 1089-1099.
13. + suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J. Immunother. 26: 85-93.
14. Chen, Y.-T., M. J. Scanlan, U. Sahin, O. Tureci, A. O. Cure, S. Tsang, B. Williamson, E. Stockert, M. Pfreundschuh, and L. J. Old. 1997. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94: 1914-1918.
15. Sahin, U., O. Tureci, H. Schmitt, B. Cochlovius, T. Johannes, R. Schmits, F. Stenner, G. Luo, I. Schobert, and M. Pfreundschuh. 1995. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA 92: 11810-11813.
16. Jager, E., Y.-T. Chen, J. W. Drijfhout, J. Karbach, M. Ringhoffer, D. Jager, M. Arand, H. Wada, Y. Noguchi, E. Stockert, et al. 1998. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187: 265-270.
17. Jager, E., Y. Nagata, S. Gnjatic, H. Wada, E. Stockert, J. Karbach, P. R. Dunbar, S. Y. Lee, A. Jungbluth, D. Jager, et al. 2000. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl. Acad. Sci. USA 97: 4760-4765.
18. + T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc. Natl. Acad. Sci. USA 100: 8862-8867.
19. Danke, N. A., D. M. Koelle, C. Yee, S. Beheray, and W. W. Kwok. 2004. Autoreactive T cells in healthy individuals. J. Immunol. 172: 5967-5972.
20. + helper T cell responses in cancer patients. Blood 106: 1008-1011.
21. + cancers. Proc. Natl. Acad. Sci. USA 97: 12198-12203.
22. + T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res. 62: 3630-3635.
23. + T cell responses in humans. Proc. Natl. Acad. Sci. USA 101: 10697-10702.
24. + T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc. Natl. Acad. Sci. USA 98: 3964-3969.
25. Stocken, E., E. Jager, Y.-T. Chen, M. J. Scanlan, I. Gout, J. Karbach, M. Arand, A. Knuth, and L. J. Old. 1998. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med, 187: 1349-1354.
26. + T cell responses against viral and tumor antigens using T cells as novel target APC, J. Immunol. Methods 278: 57-66.
27. Nagata, Y., S. Ono, M. Matsuo, S. Gnjatic, D. Valmori, G. Ritter, W. Garrett, L. J. Old, and I. Mellman. 2002. Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc. Natl. Acad. Sci. USA 99: 10629-10634.
28. + T-cell responses to the tumor-specific antigen NY-ESO-1. J. Immunother. 28: 252-257.
29. Matsuo, M., Y. Nagata, E. Sato, D. Atanackovic, D. Valmori, Y.-T. Chen, G. Ritter, I. Mellman, L. J. Old, and S. Gnjatic. 2004. IFN-γ enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. Proc. Natl. Acad. Sci. USA 101: 14467-14472.
30. + T cells restrain the maturation and antigen-presenting function of dendritic cells. J. Immunol. 172: 4676-4680.
31. + immunoregulatory cells. J. Immunol. 167: 1137-1140.
32. Gotter, J., B. Brors, M. Hergenhahn, and B. Kyewski. 2004. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J. Exp, Med. 199: 155-166.
33. Yang, Y., C. T. Huang, X. Huang, and D. M. Pardoll. 2004. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 5: 508-515.
34. + T cell-mediated suppression by dendritic cells. Science 299: 1033-1036.
35. Pasare, C., and R. Medzhitov. 2004. Toll-dependent control mechanisms of CD4 T cell activation. Immunity 21: 733-741.
36. + regulatory T cells. J. Exp. Med. 201: 681-686.
37. + regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198: 235-247.
38. + regulatory T cells in vivo. J. Exp. Med. 198: 249-258.
39. Apostolou, I., and H. von Boehmer. 2004. In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. 199: 1401-1408.
40. Kretschmer, K., I. Apostolou, D. Hawiger, K. Khazaie, M. C. Nussenzweig, and H. von Boehmer. 2005. Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 6: 1219-1227.
41. + regulatory T cells and their ligands: implications for immunotherapy. Immunity 20: 107-118.
42. + immunoregulatory T cells is antigen nonspecific. J. Immunol. 164: 183-190.
43. Dudley, M. E., and S. A. Rosenberg. 2003. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 3: 666-675.
44. Scanlan, M. J., A. O. Gure, A. A. Jungbluth, L. J. Old, and Y.-T. Chen. 2002. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188: 22-32.
45. Jager, E., D. Jager, and A. Knuth. 2003. Antigen-specific immunotherapy and cancer vaccines. Int. J. Cancer 106: 817-820.
46. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915.
47. Belardelli, F., M. Ferrantini, G. Parmiani, J. Schlom, and E. Garaci. 2004. International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? Cancer Res. 64: 6827-6830.